What is the role of canrenone in the treatment of idiopathic hyperaldosteronism?

Updated: Sep 08, 2020
  • Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Robert P Hoffman, MD  more...
  • Print

Canrenone is an active metabolite of spironolactone with a long half-life, which is currently available only in Europe. Canrenone has been shown to improve diastolic function in patients with primary hypertension independently of effects on BP and LV mass regression, suggesting a direct myocardial effect. Both canrenone and potassium canrenoate, its open E-ring water soluble congener, might be considered, in that they possibly have fewer sex steroid-related side effects.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!